



**Media Contacts:**

Corindus Vascular Robotics  
Tal Wenderow  
(508) 653-3335 ext. 205  
[Tal.Wenderow@corindus.com](mailto:Tal.Wenderow@corindus.com)

Schwartz MSL  
Krystin Hayward/ Jessica Wolter  
(781) 684-0770  
[corindus@schwartzmsl.com](mailto:corindus@schwartzmsl.com)

**ACC 2012—CHICAGO**

**ACUTE RESULTS OF THE CORPATH PRECISE TRIAL FOR ROBOTIC-ASSISTED PCI  
TO BE PRESENTED AT ACC 2012**

***Data from the trial demonstrates safety and efficacy of robotic-assisted PCI;  
The CorPath® 200 System will also be featured in ACC's Heart of Innovation Destination***

**NATICK, Mass.—March 22, 2012**—Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that data and acute results from its CorPath PRECISE Trial will be presented during a scientific presentation, “CorPath-PRECISE: Final Results of The First Pivotal Study For Robotically-Enhanced PCI” at the American College of Cardiology’s (ACC) 61<sup>st</sup> Annual Scientific Session & Expo, ACC 2012. The presentation will take place on Sunday, March 24 at 8:15 a.m. in the Expo Hall, room 1076 at McCormick Hall in Chicago.

The PRECISE trial enrolled 164 patients over nine clinical sites. Dr. Joseph Carrozza, Chief of Cardiovascular Medicine at St. Elizabeth’s Medical Center in Boston, Mass. and Dr. Giora Weisz, Director of Clinical Cardiovascular Research at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Associate Professor of Medicine at Columbia University College of Physicians and Surgeons in New York served as the co-principal investigators of the trial.

“The primary endpoints for the PRECISE trial were met, showing excellent clinical and procedural results,” said Dr. Weisz, who will present the results of the study. “Additionally, the PRECISE study demonstrated that the CorPath 200 System is a safe and effective alternative to manual PCI, has excellent clinical and device success rates, and provides radiation exposure protection to the interventional cardiologist.”

According to previous data published in the [Catheterization and Cardiovascular Intervention journal](#), the daily exposure to radiation and the physical stresses inherent in the cath lab can result in interventional cardiologists developing orthopedic problems, cataracts and cancer. The CorPath 200 System allows interventional cardiologists to perform PCI procedures in a comfortable seated position in a radiation-protected cockpit. In addition to providing an optimal view of the monitors, physicians utilize a joystick to perform precise robotic-assisted placements of coronary guidewires and stent/balloon catheters.

Dr. George Vetrovec, Professor of Medicine, Division of Cardiology, VCU Pauley Heart Center, Virginia Commonwealth University Medical Center, will also present his experience with the CorPath 200 System during his presentation, “Robotic-Assisted PCI: Opportunities for Improved Precision and Efficiency” on Saturday, March 24 at 12:35 p.m.

“I was very impressed with the precision of the CorPath 200 System and the millimeter-by-millimeter control. I was able to precisely control the stent positioning, while the CorPath 200 System provided a stable platform to fixate the guidewire in position,” said Dr. Vetrovec. “The cockpit’s seated position allowed me to view the angiography screens up close in order to treat the patient. The enhanced visualization and control that the CorPath 200 System provides has the potential to enhance efficiency in the cath lab.”

Additionally, Corindus Vascular Robotics will participate in ACC’s “Heart of Innovation Featured Learning Destination,” which explores the past, present, and future state of care for coronary artery disease and heart failure. The robotic-assisted system will be demonstrated throughout the meeting at The Heart of Innovation, taking place in hall A1, room #1076.

“We are excited with the results of the CorPath PRECISE trial and the feedback we received from our investigators using the CorPath 200 System,” said David M. Handler, President and CEO of Corindus. “We feel this technology offers interventional cardiologists a surprisingly simple solution to address the increasing challenges of healthcare quality and economics, while potentially improving the health and safety of the cath lab staff.”

To learn more about the CorPath 200 System or reserve hands-on demonstrations of the CorPath 200 System at booth 3097, please call 508.653.3335 x200 or email [info@corindus.com](mailto:info@corindus.com).

#### **About Corindus Vascular Robotics**

Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions. The Company’s CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation shielded interventional cockpit. The CorPath open-platform technology and intellectual property will enable Corindus to address other segments of the vascular market, including peripheral, neuro and structural heart applications. Additional information can be found at: <http://www.corindus.com>

*NOTE: The CorPath 200 System is an investigational device and limited by federal law to investigational use only.*